![Judith S. Pelton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Judith S. Pelton
Secrétaire Général chez Phage Biotechnology Corp.
Postes actifs de Judith S. Pelton
Sociétés | Poste | Début | Fin |
---|---|---|---|
Phage Biotechnology Corp.
![]() Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | Secrétaire Général | - | - |
Historique de carrière de Judith S. Pelton
Anciens postes connus de Judith S. Pelton
Sociétés | Poste | Début | Fin |
---|---|---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Secrétaire Général | - | - |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Corporate Secretary | 2 |
Sectorielle
Commercial Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
Phage Biotechnology Corp.
![]() Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | Health Technology |
- Bourse
- Insiders
- Judith S. Pelton
- Expérience